Sage Therapeutics Inc. (SAGE)
Symbol Info
Listed Symbol SAGE
Name Sage Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $90,273,000
Latest Fiscal EPS $-8.07
Price Info
21 Day Moving Average $166.7514
21 Day EMA $167.265270
50 Day Moving Average $174.3064
50 Day EMA $170.455230
200 Day EMA $159.075260
200 Day Moving Average 150.241040
52 Week High $193.56
52 Week Low $79.88
52 Week Change $8.688400
Alpha 0.030354
Beta 2.5461
Standard Deviation 0.204626
R2 0.186370
Periods 60
Share Information
10 Day Average Volume 347,377
20 Day Average Volume 400,461
30 Day Average Volume 384,431
50 Day Average Volume 347,187
Outstanding Shares 51,656,993
Float Shares 50,809,662
Percent Float 98.36%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 559
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 9,252,853
Institute Holdings Percent -
Institute Sold Previous 3 Months 4,364,375
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 134,987
Insider Holdings Percent 1.70%
Insider Sold Previous 3 Months 134,264
Insiders Shares Owned 847,331
Price Change
7 Day Price Change $-7.2899933
7 Day Percent Change -4.31%
21 Day Price Change $-4.4900055
21 Day Percent Change -2.70%
30 Day Price Change $-18.259995
30 Day Percent Change -10.13%
Month To Date Price Change $1.6600
Month To Date Percent 1.04%
90 Day Price Change $-8.320007
90 Day Percent Change -4.88%
Quarter To Date $-21.089996
Quarter To Date Percent -11.52%
180 Day Price Change $1.070007
180 Day Percent Change 0.66%
200 Day Price Change $32.920000
200 Day Percent Change 25.50%
Year To Date $66.210000
Year To Date Percent 69.12%
Profile
Description Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.
Details
Issue Type CS
Market Cap $8,368,432,866
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 51,656,993
CEO Jeffrey M. Jonas
Employees 637
Last Audit UQ
Classification
CIK 0001597553
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 215 First Street
Cambridge, MA 2142
Website http://www.sagerx.com
Facisimile +1 617 299-8379
Telephone +1 617 299-8380
Email paul.cox@sagerx.com
Key Ratios
Profitability
EBIT Margin -39,682.2
EBITDA Margin -39,584.8
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 95.00
Profit Margin TOT -
Income Statements
Revenue $1,611,000
Revenue Per Share $0.0312
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $7,115,085,582
Price To Sales 5,194.557600
Price To Free Cash -17.7
PE High Last 5 Years -
Price To Book 6.9
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 6.9
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 16.0
Leverage Ratio 1.1
Quick Ratio 15.7
Long Term Debt To Capital 0.03
Assets
Receivables Turnover 0.2
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -50.14
Return On Equity -53.75
Return On Capital -52.23
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SAGE
Sage Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.